Hundreds of lawsuits claim Ozempic, Wegovy and Mounjaro GLP-1 drugs caused permanent vision loss
AI Market Summary
Hundreds of lawsuits allege GLP-1 drugs (including Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound) caused NAION-related vision loss and that warnings were insufficient in the US. Rising claim volume and litigation risk can increase uncertainty around product safety, labeling, and potential settlement or regulatory costs, pressuring near-term risk appetite toward affected pharma equities and related healthcare exposure.
Impact level
● Medium
Affected assets
NCSKNVO2USD/USDT-1.08%
AI Insight · NCSKNVO2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Hundreds of lawsuits accuse Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and other GLP-1 drugs of causing permanent vision loss. Plaintiffs argue the companies should have known about the risk but did not disclose it on U.S. warning labels. One 63-year-old man with diabetes allegedly lost vision in one eye after taking Ozempic and later became legally blind, and a Phoenix law firm says it has received nearly 200 inquiries, with some cases filed in states including Arizona.
